CVS Health is to divide its US retail pharmacy chain from its Aetna insurance and Caremark pharmacy-benefit businesses, dismantling a healthcare group valued at $117 billion after years of consolidation. The company said on Wednesday that it expects to complete the separation during the first half of 2028.
Shares fell sharply after the announcement, dropping 12.6% to $79.94. The market reaction came despite CVS reporting stronger-than-expected quarterly earnings and issuing a 2027 profit forecast above the current analyst consensus. The planned break-up therefore represents a significant test of whether investors believe a simpler corporate structure can create more value than the integrated model the group has spent years constructing.
A return to a simpler structure
The transaction would return CVS to being a standalone pharmacy chain for the first time since 2006. That was the year in which it acquired Caremark, the pharmacy-benefit manager that became part of a wider expansion into healthcare services. CVS subsequently added Aetna, bringing retail pharmacies, insurance and pharmacy-benefit operations under one corporate umbrella.
Chief executive David Joyner said the three businesses had made marked progress over the past two years. He pointed to the company’s chain of 9,000 pharmacies, its Caremark operation and Aetna as businesses that are now performing well enough to support a different organisational approach.
“The businesses are running really well.”
Mr Joyner also said CVS had beaten Wall Street expectations in each of the last eight quarters. Its latest results continued that run: third-quarter earnings were $2.09 per share, compared with the average analyst estimate of $1.65, according to LSEG data.
Forecast points to earnings confidence
CVS forecast adjusted earnings of at least $8.65 per share for 2027. That figure is above analysts’ estimate of $8.53 per share, suggesting management is presenting the restructuring alongside a relatively confident near-term outlook for the underlying businesses.
| Measure | Figure |
|---|---|
| CVS Health value | $117 billion |
| Share price move after announcement | Down 12.6% to $79.94 |
| Third-quarter earnings | $2.09 per share |
| Analyst estimate for third-quarter earnings | $1.65 per share |
| Minimum 2027 adjusted earnings forecast | $8.65 per share |
The decision reflects a wider shift among large companies towards separating operations that have become difficult to manage within a single group. CVS said the division would make different decisions possible now that the individual businesses had improved. The move also places the company among a series of major corporate break-ups announced during this decade, as groups seek to simplify their structures and improve returns for shareholders.
Regulatory pressure on vertical integration
The restructuring comes amid criticism of the healthcare industry’s consolidation. Opponents argue that bringing insurers, pharmacies and pharmacy-benefit managers together can create conflicts of interest and has contributed to rising healthcare spending in the United States, where costs are the highest in the world.
Morningstar analyst Julie Utterback said vertically integrated managed-care organisations had faced increasing scrutiny from regulators and customers. She described CVS as the company with the industry’s greatest exposure to that model, and said its management may have preferred to act before a legal or legislative decision forced a change.
“Management probably thought that it was a better time to move somewhat pre-emptively rather than wait for a legal or legislative decision that forced their hand.”
That pressure gives the break-up a significance beyond balance-sheet design. Separating the operations could reduce the concentration of potential conflicts that critics have highlighted, while also leaving investors and regulators to assess the businesses on a more distinct basis. The proposal, however, remains a long-dated change: CVS is targeting completion in 2028, meaning the company will continue to operate its current combined structure while the separation is prepared.
- Retail pharmacies: CVS’s network of 9,000 outlets would be separated from the other operations.
- Insurance: Aetna would leave the retail pharmacy structure.
- Pharmacy benefits: Caremark would be separated alongside the insurance business.
For CVS, the central question is whether the two resulting structures can deliver more focused management and stronger shareholder returns than the conglomerate model. Wednesday’s share-price fall shows that investors remain cautious, even after the earnings beat and the forecast for 2027. The company now has to turn a strategic announcement into a workable separation while maintaining performance across the businesses that made the transaction possible.
